Edwards Lifesciences Corp (NYSE: EW) kicked off on Tuesday, down -1.32% from the previous trading day, before settling in for the closing price of $78.21. Over the past 52 weeks, EW has traded in a range of $58.93-$95.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.36%. While this was happening, its average annual earnings per share was recorded 1.67%. With a float of $574.69 million, this company’s outstanding shares have now reached $586.20 million.
Considering the fact that the conglomerate employs 15800 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 79.18%, operating margin of 26.75%, and the pretax margin is 29.13%.
Edwards Lifesciences Corp (EW) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Edwards Lifesciences Corp is 2.03%, while institutional ownership is 87.77%. The most recent insider transaction that took place on Jun 16 ’25, was worth 673,268. In this transaction Global President TAVR & Surg of this company sold 8,950 shares at a rate of $75.23, taking the stock ownership to the 206,900 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 8,950 for $75.23, making the entire transaction worth $673,268.
Edwards Lifesciences Corp (EW) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.56% during the next five years compared to -2.36% drop over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Take a look at Edwards Lifesciences Corp’s (EW) current performance indicators. Last quarter, stock had a quick ratio of 3.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.17. Likewise, its price to free cash flow for the trailing twelve months is 71.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.50, a number that is poised to hit 0.62 in the next quarter and is forecasted to reach 2.76 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Compared to the last year’s volume of 4.55 million, its volume of 4.2 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 90.70%.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 87.74%, which indicates a significant increase from 77.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.51% in the past 14 days, which was lower than the 25.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $75.76, while its 200-day Moving Average is $71.74. Nevertheless, the first resistance level for the watch stands at $77.83 in the near term. At $78.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $78.94. If the price goes on to break the first support level at $76.72, it is likely to go to the next support level at $76.27. Now, if the price goes above the second support level, the third support stands at $75.61.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
The company with the Market Capitalisation of 45.27 billion has total of 586,600K Shares Outstanding. Its annual sales at the moment are 5,440 M in contrast with the sum of 4,175 M annual income. Company’s last quarter sales were recorded 1,413 M and last quarter income was 358,000 K.
